Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.73 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.59 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.59 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.59 |
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.59 |
| ▸ | PIM1 | P11309 | 1/20 | 0.59 |
| ▸ | PRKACA | P17612 | 1/20 | 0.59 |
| ▸ | LTK | P29376 | 1/20 | 0.59 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.59 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.59 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.59 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.59 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.59 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.59 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.59 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.59 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.59 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18354383 | 0.85 | EGFR (0.65) | EGFRCLK4LMNACYP1A2CYP3A4 | |
| SCHEMBL7975392 | 0.85 | EGFR (0.73) | EGFRERBB2MAPK1HTTHIF1A | |
| SCHEMBL2988440 | 0.85 | EGFR (1.00) | EGFRABCG2ERBB2 | |
| SCHEMBL7978403 | 0.85 | EGFR (0.73) | EGFRABL1ERBB2MAPK14MAPK1 | |
| SCHEMBL7965118 | 0.83 | EGFR (0.73) | EGFRABCG2HTTKDRBRAF | |
| SCHEMBL11965408 | 0.82 | EGFR (0.78) | EGFRABCG2DAPK3MAP4K4ABL1 | |
| SCHEMBL868020 | 0.82 | EGFR (0.68) | EGFRABCG2DAPK3ABL1ERBB2 | |
| SCHEMBL13151521 | 0.80 | RET (0.60) | EGFRRETKDRRAF1BRAF | |
| SCHEMBL11902821 | 0.80 | EGFR (0.70) | EGFRABCG2ERBB2KDM4ELMNA | |
| SCHEMBL11902904 | 0.80 | GRM1 (0.64) | EGFRERBB2AURKBKDRCD38 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1997026259-A1 | IMPROVED PROCESS FOR PREPARING 4,6-DISUBSTITUTED PYRIDO[3,4-d]PYRIMIDINES | WARNER-LAMBERT COMPANY (US) | 1997-07-24 | — | — | WO | claimed |
| US-20160031877-A1 | KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-02-04 | — | — | US | disclosed |
| US-20160031877-A1 | KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-02-04 | — | — | US | disclosed |
| US-9101632-B2 | Kinase inhibitors, prodrug forms thereof and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-08-11 | — | — | US | disclosed |
| US-9101632-B2 | Kinase inhibitors, prodrug forms thereof and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-08-11 | — | — | US | disclosed |
| US-20120202832-A1 | KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-08-09 | — | — | US | disclosed |
| US-20120202832-A1 | KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-08-09 | — | — | US | disclosed |
| US-6313292-B1 | REACTION FROM 5-AMINO-2-FLUOROPYRIDINE; AMINATION, CYCLIZATION, CHLORINATION, SALT FORMATION, DECHLORINATION, DEBLOCKING | WARNER-LAMBERT COMPANY | 2001-11-06 | — | — | US | disclosed |
| WO-1997026259-A1 | IMPROVED PROCESS FOR PREPARING 4,6-DISUBSTITUTED PYRIDO[3,4-d]PYRIMIDINES | WARNER-LAMBERT COMPANY (US) | 1997-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031877-A1 | KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY | ERBB2, MAP3K3, ERBB3 | EGFR 110/4885ABCG2 1846/4885DAPK3 383/4885 |
| US-20120202832-A1 | KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY | ERBB2, MAP3K3, MAP3K19 | EGFR 110/4885ABCG2 2026/4885DAPK3 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.